BioSpace News Archive

Policy

Novartis Cosentyx receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis

Novartis, a leader in rheumatology and immuno-dermatology, announced that the US Food and Drug Administration has approved Cosentyx® for the treatment of active non-radiographic axial spondyloarthritis, confirming Cosentyx efficacy in addressing the axial spondyloarthritis disease spectrum9.

June 16, 2020
·
15 min read
Deals

AVEO Announces Pricing of $44.6 Million Public Offering of Common Stock

AVEO Oncology announced that it has priced its previously announced underwritten public offering of 8,500,000 shares of its common stock at a price to the public of $5.25 per share.

June 16, 2020
·
4 min read
Deals

Actinium Pharmaceuticals, Inc. Announces Pricing of $25.0 Million Public Offering

Actinium Pharmaceuticals, Inc. announced the pricing of its previously announced public offering of 76,923,077 shares of its common stock at a price to the public of $0.325 per share of common stock.

June 16, 2020
·
5 min read